{
  "query": "free progression",
  "studies": {
    "protocolSection": [
      {
        "identificationModule": {
          "nctId": "NCT07172386",
          "briefTitle": "Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma (RCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05364905",
          "briefTitle": "Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Oncology", "Endometrial Cancer", "Advanced Cancer", "Recurrent Cancer", "Metastatic Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01908556",
          "briefTitle": "Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-02"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients."
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3545,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05653622",
          "briefTitle": "Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma Multiforme, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 75,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02260531",
          "briefTitle": "Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Brain Tumor - Metastatic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02468557",
          "briefTitle": "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-04-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Previously Untreated Pancreatic Ductal Adenocarcinoma", "Relapsed/Refractory Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04425681",
          "briefTitle": "Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leptomeningeal Metastasis", "Non-small Cell Lung Cancer", "EGFR Activating Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02839681",
          "briefTitle": "Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-07-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05961319",
          "briefTitle": "Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Frailty", "Frailty Syndrome", "Frail Elderly Syndrome", "Pre-Frailty", "Healthy", "Healthy Aging", "Aging Problems", "Aging Disorder"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05519319",
          "briefTitle": "Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Extrahepatic Cholangiocarcinoma", "Bile Duct Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05334719",
          "briefTitle": "A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Stomach Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01878708",
          "briefTitle": "A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2017-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["T-Cell Lymphoma", "Relapsed T-Cell Lymphoma", "Refractory T-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04875325",
          "briefTitle": "Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Resectable Pancreatic Ductal Adenocarcinoma", "Recurrent Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 306,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07263425",
          "briefTitle": "Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-27",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Leptomeningeal Metastasis of HER2-positive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05176925",
          "briefTitle": "Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-09-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03590210",
          "briefTitle": "Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-06-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-02-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Adult Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 92,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02457910",
          "briefTitle": "Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-08-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Progesterone Receptor Negative", "Progesterone Receptor Positive", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03306420",
          "briefTitle": "First-in-Human Study of MS201408-0005A as Single Agent and in Combinations"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic or Locally Advanced Unresectable Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02838420",
          "briefTitle": "A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 187,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06674382",
          "briefTitle": "Haplo-HSCT for Myelofibrosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Myelofibrosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06232759",
          "briefTitle": "TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-04-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01005680",
          "briefTitle": "A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-11"
          },
          "completionDateStruct": {
            "date": "2012-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 256,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01631279",
          "briefTitle": "A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-08"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Unspecified Adult Solid Tumor, Protocol Specific"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04316546",
          "briefTitle": "MK-7075 (Miransertib) in Proteus Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Proteus Syndrome"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "3 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06817161",
          "briefTitle": "Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Carcinoma", "First Line Chemotherapy", "Digestive System Disorders"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 116,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04473027",
          "briefTitle": "BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-04-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06662669",
          "briefTitle": "YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06254469",
          "briefTitle": "Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Alzheimer Disease", "Chronic Traumatic Encephalopathy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 230,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "45 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06155383",
          "briefTitle": "Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06749340",
          "briefTitle": "Examining the Effects of Different Resistive Exercise Programs in Individuals with Compensated Liver Cirrhosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-23",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Coginitive Dysfunction", "Compensated Liver Cirrhosis", "Physical Dysfunction", "Sarcopenia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "40 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05869240",
          "briefTitle": "BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-05-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 388,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00974389",
          "briefTitle": "S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-07"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04524689",
          "briefTitle": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00506168",
          "briefTitle": "Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2001-11"
          },
          "completionDateStruct": {
            "date": "2007-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Colorectal Neoplasms", "Secondary", "Drug Therapy, Combination"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05920668",
          "briefTitle": "Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-07-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "CLL/SLL"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04905810",
          "briefTitle": "Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00311610",
          "briefTitle": "Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-01"
          },
          "completionDateStruct": {
            "date": "2010-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03233360",
          "briefTitle": "Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2533,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06514313",
          "briefTitle": "Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 110,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06823960",
          "briefTitle": "Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Marginal Zone Lymphoma(MZL)"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 59,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00358982",
          "briefTitle": "Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-08"
          },
          "completionDateStruct": {
            "date": "2009-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hodgkin's Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00089479",
          "briefTitle": "A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-08"
          },
          "completionDateStruct": {
            "date": "2012-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2611,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07247396",
          "briefTitle": "CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peritoneal Metastases From Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00702962",
          "briefTitle": "Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2012-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00077246",
          "briefTitle": "ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2003-09"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 64,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05557903",
          "briefTitle": "Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma, Non-Hodgkin", "Lymphoma, T-Cell"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05068427",
          "briefTitle": "Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-11-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04625803",
          "briefTitle": "Neoadjuvant Therapy for Locally Advanced Colon Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Cancer", "Neoadjuvant Therapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05548127",
          "briefTitle": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00807027",
          "briefTitle": "Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-12-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 180,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02124746",
          "briefTitle": "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-12-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis", "Polycythemia Vera", "Essential Thrombocythemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 87,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05022342",
          "briefTitle": "Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01319942",
          "briefTitle": "Combined Radiotherapy and Sorafenib in Patients With Hepatoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-06"
          },
          "completionDateStruct": {
            "date": "2013-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "69 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03783442",
          "briefTitle": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Squamous Cell Carcinoma (ESCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 649,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01520870",
          "briefTitle": "Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-02"
          },
          "completionDateStruct": {
            "date": "2017-03-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Brain Tumor, Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 49,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01896869",
          "briefTitle": "FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-05-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 83,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07284069",
          "briefTitle": "Senicapoc and Perampanel for Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04136769",
          "briefTitle": "Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-02-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreas Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00510354",
          "briefTitle": "Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10"
          },
          "completionDateStruct": {
            "date": "2012-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Progressive Gastrointestinal Stromal Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "30 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01803269",
          "briefTitle": "Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-03-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Extensive Stage Small Cell Lung Cancer", "Recurrent Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04958239",
          "briefTitle": "A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03606577",
          "briefTitle": "An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04152577",
          "briefTitle": "R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, B-Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05888675",
          "briefTitle": "Clinical Study of Weifuchun Treatment on Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer (Diagnosis)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04873375",
          "briefTitle": "Cemiplimab for Secondary Angiosarcomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-10-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Secondary Angiosarcoma", "Locally Advanced Sarcoma", "Metastasis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05569512",
          "briefTitle": "Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Pediatric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "39 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03023319",
          "briefTitle": "Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Non-Small-Cell Lung", "Mesothelioma", "Bladder Cancer", "Ovarian Cancer", "Peritoneal Cancer", "Thymoma", "Thymus Cancer", "Uterine Cervical Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02389400",
          "briefTitle": "Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01"
          },
          "completionDateStruct": {
            "date": "2017-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Langerhans Cell Histiocytosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03693807",
          "briefTitle": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Colorectal Cancer", "Cholangiocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03958136",
          "briefTitle": "Clinico-biological Data Collection Study of Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2036-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 289,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06764836",
          "briefTitle": "A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-27",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Solid Tumors", "HCC"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 108,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01953536",
          "briefTitle": "Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04"
          },
          "completionDateStruct": {
            "date": "2016-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00450736",
          "briefTitle": "Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-03"
          },
          "completionDateStruct": {
            "date": "2009-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Childhood Malignant Fibrous Histiocytoma of Bone", "Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00271271",
          "briefTitle": "Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2003-06"
          },
          "completionDateStruct": {
            "date": "2006-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03764371",
          "briefTitle": "Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gene Mutation"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06532344",
          "briefTitle": "An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07261709",
          "briefTitle": "Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Refractory Metastatic Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 236,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04318834",
          "briefTitle": "Molecular Profiling of Advanced Biliary Tract Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-04-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Biliary Tract Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03086993",
          "briefTitle": "Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Bile Duct Cancer", "Intrahepatic Cholangiocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 295,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03963193",
          "briefTitle": "Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrointestinal Neuroendocrine Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 112,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04764214",
          "briefTitle": "SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["NSCLC Stage IV", "EGFR Activating Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02154737",
          "briefTitle": "Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2020-09-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06695845",
          "briefTitle": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Cancer", "Colorectal Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Urothelial Carcinoma", "Salivary Gland Cancer", "Pancreatic Cancer", "HER-2 Protein Overexpression"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03810339",
          "briefTitle": "Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor", "Advanced Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06644677",
          "briefTitle": "Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cervical Cancers", "HPV Testing", "Nanopore Sequencing", "HPV Integration Site Detection", "Rapid Diagnosis"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "75 Years",
          "maximumAge": "78 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02767557",
          "briefTitle": "Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-01-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Unresectable Pancreatic Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 147,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128501",
          "briefTitle": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia", "Therapy-Related Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02597465",
          "briefTitle": "A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2019-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Biliary Tract Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02718365",
          "briefTitle": "Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Neoplasms", "Surgery"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1382,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00493467",
          "briefTitle": "Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-06"
          },
          "completionDateStruct": {
            "date": "2022-08-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02028507",
          "briefTitle": "Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-01-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 693,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01428492",
          "briefTitle": "Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12"
          },
          "completionDateStruct": {
            "date": "2015-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00248534",
          "briefTitle": "Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-09"
          },
          "completionDateStruct": {
            "date": "2012-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03457844",
          "briefTitle": "A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastroenteropancreatic Neuroendocrine Tumor G3"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00283244",
          "briefTitle": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2014-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 147,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01548534",
          "briefTitle": "A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-02"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Breast Cancer", "Progesterone Receptor Positive Tumor", "Estrogen Receptor Positive Tumor", "HER-2 Negative Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06348134",
          "briefTitle": "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "HER2-positive Breast Cancer", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00531687",
          "briefTitle": "Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-09"
          },
          "completionDateStruct": {
            "date": "2016-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Testicular Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04684563",
          "briefTitle": "huCART19-IL18 in CD19+ Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2036-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia", "Non-hodgkin Lymphoma", "Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03680521",
          "briefTitle": "Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-10-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Clear Cell Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.1": [
      {
        "identificationModule": {
          "nctId": "NCT03126019",
          "briefTitle": "A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 126,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05930665",
          "briefTitle": "Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pleural Mesothelioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128800",
          "briefTitle": "Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07092007",
          "briefTitle": "NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Intraepithelial Neoplasia", "Cervical Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03929107",
          "briefTitle": "Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "B Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04003636",
          "briefTitle": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-04-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Biliary Tract Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1069,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04681911",
          "briefTitle": "Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-09-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01649336",
          "briefTitle": "A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05856864",
          "briefTitle": "Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01508364",
          "briefTitle": "Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07"
          },
          "completionDateStruct": {
            "date": "2013-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Renal Cell"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01062399",
          "briefTitle": "Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-12"
          },
          "completionDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 279,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00496132",
          "briefTitle": "A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-08-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2009-06-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Lymphocytic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03454763",
          "briefTitle": "Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 618,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03895463",
          "briefTitle": "Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-03-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01839487",
          "briefTitle": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-05-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-09-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 279,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03219593",
          "briefTitle": "Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Apatinib", "Biomarker"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00466687",
          "briefTitle": "Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-09"
          },
          "completionDateStruct": {
            "date": "2008-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04608487",
          "briefTitle": "Axi-cel in CNS Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2038-06-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma", "Lymphoma Cns"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05394493",
          "briefTitle": "An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 130,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01395121",
          "briefTitle": "A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-12-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Mucosal Lentiginous Melanoma", "Acral Lentiginous Malignant Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00247416",
          "briefTitle": "Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-08"
          },
          "completionDateStruct": {
            "date": "2009-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IV Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01603004",
          "briefTitle": "Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-05-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-06-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Neuroendocrine Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02324439",
          "briefTitle": "Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-03"
          },
          "completionDateStruct": {
            "date": "2021-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03568539",
          "briefTitle": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-06-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced/Metastatic Solid Malignancies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06730477",
          "briefTitle": "Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Adenocarcinoma", "EGFR Activating Mutation"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05458401",
          "briefTitle": "EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "HER2-positive Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 256,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02322281",
          "briefTitle": "TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02"
          },
          "completionDateStruct": {
            "date": "2018-03-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 149,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04900428",
          "briefTitle": "Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Covid19"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 179,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04708067",
          "briefTitle": "Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-02-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Locally Advanced Intrahepatic Cholangiocarcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05821192",
          "briefTitle": "Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06876844",
          "briefTitle": "Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Head and Neck Cancer Squamous Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02393209",
          "briefTitle": "Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-01-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06963632",
          "briefTitle": "A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peripheral T-cell Lymphoma (PTCL)"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04888663",
          "briefTitle": "Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-09-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent/Metastatic Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07220187",
          "briefTitle": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-05-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07234487",
          "briefTitle": "Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 178,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03578198",
          "briefTitle": "Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-04-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "CD20-positive Non-Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00345163",
          "briefTitle": "A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2007-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 167,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03319901",
          "briefTitle": "Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03864419",
          "briefTitle": "Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Burkitt Lymphoma", "KSHV-associated Multicentric Castleman Disease", "Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04374630",
          "briefTitle": "Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Platinum-resistant Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04104230",
          "briefTitle": "Quebec Pancreas Cancer Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-03-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreas Cancer", "Pancreatic Cancer", "Pancreas Neoplasm", "Pancreas Cyst", "Pancreatic Precancerous Condition", "Familial Pancreatic Cancer", "Hereditary Cancer", "Bile Duct Cancer", "Ampullary Cancer", "Duodenal Cancer", "Gallbladder Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01960192",
          "briefTitle": "Treatment of Primary CNS Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06"
          },
          "completionDateStruct": {
            "date": "2020-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Primary CNS Lymphoma (PCNSL)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "14 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03741244",
          "briefTitle": "TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 211,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03739944",
          "briefTitle": "Different Surgical Approaches in Patients of Early-stage Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-11-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Uterine Cervical Neoplasm", "Laparotomy", "Laparoscopy", "Survival", "Mortality", "Morbidity", "Quality of Life", "Pelvic Floor Disorders", "Cost-Benefit Analysis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 700,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03286244",
          "briefTitle": "Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06495164",
          "briefTitle": "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Malignant Neoplasm of Breast"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05301764",
          "briefTitle": "A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03971409",
          "briefTitle": "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Triple-Negative Breast Carcinoma", "Unresectable Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01068509",
          "briefTitle": "Ovarian Cancer Vaccine for Patients in Remission"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-07"
          },
          "completionDateStruct": {
            "date": "2015-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Epithelial Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00390299",
          "briefTitle": "Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Mixed Glioma", "Recurrent Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03196232",
          "briefTitle": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-05-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Unresectable Esophageal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01530698",
          "briefTitle": "Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-04"
          },
          "completionDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04956198",
          "briefTitle": "Drug Sensitivity and Mutation Profiling"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Ewing Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma", "Wilms Tumor", "Sarcoma, Spindle Cell", "Sarcoma Rhabdoid", "Childhood Sarcoma of Soft Tissue"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07122687",
          "briefTitle": "IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 170,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04923893",
          "briefTitle": "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2036-09-22",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 743,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00509093",
          "briefTitle": "Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-10"
          },
          "completionDateStruct": {
            "date": "2015-04-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02917993",
          "briefTitle": "An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04533321",
          "briefTitle": "A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00975806",
          "briefTitle": "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-10-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06182306",
          "briefTitle": "Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Triple Negative Breast Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00062504",
          "briefTitle": "Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2003-07"
          },
          "completionDateStruct": {
            "date": "2006-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Mixed Oligoastrocytoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01423604",
          "briefTitle": "Study of Ruxolitinib in Pancreatic Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-07"
          },
          "completionDateStruct": {
            "date": "2016-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 136,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02524275",
          "briefTitle": "Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-03-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-10-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01420081",
          "briefTitle": "A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-01-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-12-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04532281",
          "briefTitle": "A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia", "Non-Hodgkin Lymphoma of Soft Tissue"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05316181",
          "briefTitle": "CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-04-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Epithelial Ovarian Cancer", "Platinum Resistant", "Recurrent Ovarian", "HIPEC", "Mitomycin", "Cytoreductive Surgery"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04831567",
          "briefTitle": "Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-02-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01200212",
          "briefTitle": "A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-07"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 432,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04878107",
          "briefTitle": "SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 88,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03552692",
          "briefTitle": "Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["T-Cell Lymphoma Relapsed", "T-Cell Lymphoma Refractory"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01288092",
          "briefTitle": "BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-03"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02099292",
          "briefTitle": "Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2001-05"
          },
          "completionDateStruct": {
            "date": "2014-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed Non-Hodgkin-Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 103,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04548271",
          "briefTitle": "Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05949944",
          "briefTitle": "Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peripheral T-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00125034",
          "briefTitle": "Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07"
          },
          "completionDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Neoplasm Metastasis", "Colorectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 344,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06434064",
          "briefTitle": "Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Unresectable Triple-Negative Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01431209",
          "briefTitle": "Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-08-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01482299",
          "briefTitle": "RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2014-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Stomach Neoplasm"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00097409",
          "briefTitle": "Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-12"
          },
          "completionDateStruct": {
            "date": "2007-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06305832",
          "briefTitle": "Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancer", "Biochemical Recurrence"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05606263",
          "briefTitle": "Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 55,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01512199",
          "briefTitle": "Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-01-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04469114",
          "briefTitle": "Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-01-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Covid19"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 289,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02659514",
          "briefTitle": "Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02194816",
          "briefTitle": "Modifiable Variables in Parkinsonism (MVP)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-09"
          },
          "completionDateStruct": {
            "date": "2030-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Parkinson's Disease", "Parkinsonism", "MSA - Multiple System Atrophy", "Progressive Supranuclear Palsy", "Shy-Drager Syndrome", "Corticobasal Degeneration", "Dementia With Lewy Bodies", "Pick Disease", "Olivopontocerebellar Atrophies"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02736500",
          "briefTitle": "Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-10-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroendocrine Tumors", "Gastro Entero Pancreatic Neuroendocrine Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01578707",
          "briefTitle": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed or Refractory Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 391,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04458311",
          "briefTitle": "Abiraterone Acetate in Combination With Tildrakizumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-11-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Castration Resistant Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00656136",
          "briefTitle": "BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-04"
          },
          "completionDateStruct": {
            "date": "2013-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 585,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07223034",
          "briefTitle": "A Study of 177Lu-PSMA-617 in People With Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioma", "Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)", "Glioblastoma, IDH-wildtype", "Diffuse Midline Glioma, H3 K27-Altered", "Diffuse Hemispheric Glioma, H3 G34-mutant", "Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05490771",
          "briefTitle": "Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-06-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphatic System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04152863",
          "briefTitle": "Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced/Metastatic Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 85,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05842187",
          "briefTitle": "In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Cancer", "Gastric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01863693",
          "briefTitle": "An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-05-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-06-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 300,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02872714",
          "briefTitle": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-02-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "UC (Urothelial Cancer)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 263,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00072384",
          "briefTitle": "Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-04-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Intraocular Retinoblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00990652",
          "briefTitle": "Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06197438",
          "briefTitle": "Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04808882",
          "briefTitle": "ANTIcoagulation in Severe COVID-19 Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-03-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Severe COVID-19 Pneumonia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 353,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.2": [
      {
        "identificationModule": {
          "nctId": "NCT03023124",
          "briefTitle": "Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solitary Fibrous Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04802759",
          "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-05-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 316,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03161223",
          "briefTitle": "Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, T-Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04521179",
          "briefTitle": "Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "HER2-positive Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02455596",
          "briefTitle": "Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05"
          },
          "completionDateStruct": {
            "date": "2016-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01238146",
          "briefTitle": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-10"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06835803",
          "briefTitle": "Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma (GBM)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 56,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01966003",
          "briefTitle": "Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-07-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 642,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04575961",
          "briefTitle": "Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Low Grade Serous Carcinoma", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06252870",
          "briefTitle": "Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Graft Versus Host Disease", "Hematologic Malignancy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01248273",
          "briefTitle": "Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tubes", "Ovarian Cancer", "Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01939483",
          "briefTitle": "A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12"
          },
          "completionDateStruct": {
            "date": "2018-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Central Nervous System Metastases", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04925141",
          "briefTitle": "A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-12-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Myelogenous Leukemia - Chronic Phase"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 62,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02999854",
          "briefTitle": "Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02707666",
          "briefTitle": "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-02-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pleural Mesothelioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03325166",
          "briefTitle": "Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Carcinoma Metastatic in the Brain", "Stage IV Lung Non-Small Cell Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02441322",
          "briefTitle": "Evaluating Therapeutic Response to Novo-TTF"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12"
          },
          "completionDateStruct": {
            "date": "2023-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma Multiforme"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04501029",
          "briefTitle": "A Study of Gimatecan (ST1481) in Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00308529",
          "briefTitle": "Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2009-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Small Cell Lung", "Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 55
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05797831",
          "briefTitle": "Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-07-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 268,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02599402",
          "briefTitle": "Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 533,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02184195",
          "briefTitle": "Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-01-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Germline BRCA1/2 Mutations and", "Metastatic Adenocarcinoma of the Pancreas"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 154,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02989857",
          "briefTitle": "Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-02-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cholangiocarcinoma", "Metastatic Cholangiocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 187,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03308201",
          "briefTitle": "Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-03-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 55,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01522612",
          "briefTitle": "Colorectal Cancer (CRC) Cetuximab Elderly Frail"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-04"
          },
          "completionDateStruct": {
            "date": "2015-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04059081",
          "briefTitle": "A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-07-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Lymphocytic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03760081",
          "briefTitle": "A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Incurable Platinum Refractory Germ Cell Tumors", "Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04993430",
          "briefTitle": "A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "ER-Positive, HER2-Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02897830",
          "briefTitle": "Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01952730",
          "briefTitle": "Pilot Study of GVAX in Colorectal Cancer Cells"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02109328",
          "briefTitle": "Alisertib in Chemotherapy-pretreated Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-08-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-10-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Bladder Cancer", "Transitional Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03706365",
          "briefTitle": "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 393,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05705700",
          "briefTitle": "Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05116800",
          "briefTitle": "Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Soft Tissue Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma", "Osteosarcoma", "Ewing Sarcoma of Bone"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "10 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04432207",
          "briefTitle": "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Stage IIIB", "Non-small Cell Lung Cancer Stage IV", "Squamous Non-small-cell Lung Cancer", "Large Cell Carcinoma Lung", "Adenocarcinoma Lung"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06775236",
          "briefTitle": "Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-01-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Solid Tumors", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 410,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05684211",
          "briefTitle": "A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 84,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06885671",
          "briefTitle": "Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Early Stage Breast Cancer (Stage 1-3)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00392171",
          "briefTitle": "The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-06-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2009-09-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioma", "Astrocytoma", "Oligodendroglioma", "Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04891744",
          "briefTitle": "Selinexor in Combination With Thalidomide and Dexamethasone in RRMM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-06",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06623734",
          "briefTitle": "Liver Cancer Prognosis Investigation Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2044-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Liver Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 5000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01626664",
          "briefTitle": "KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06"
          },
          "completionDateStruct": {
            "date": "2018-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Adult T-cell Leukemia-Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04736199",
          "briefTitle": "Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-02-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostatic Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 669,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03470922",
          "briefTitle": "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 714,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04474353",
          "briefTitle": "Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Newly Diagnosed Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02404753",
          "briefTitle": "A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01471353",
          "briefTitle": "Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2017-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05770037",
          "briefTitle": "DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Haematological Malignancy", "Malignant Neoplasm", "Lymphoproliferative Disorders", "Neoplasms by Histologic Type", "Neoplasms by Site", "Cancer", "Anaplastic Large Cell Lymphoma", "Lymphoma", "Renal Cell Carcinoma", "Neuroblastoma", "Solid Tumour"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04224337",
          "briefTitle": "Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-05-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02268695",
          "briefTitle": "Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-10-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 541,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "71 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05194995",
          "briefTitle": "JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Colorectal Cancer", "Small Intestinal Cancer", "Appendiceal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03520075",
          "briefTitle": "Study of ASTX029 in Subjects With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumor, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 192,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00255801",
          "briefTitle": "Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-11"
          },
          "completionDateStruct": {
            "date": "2017-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05048212",
          "briefTitle": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-09-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Brain Metastases", "Renal Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01919619",
          "briefTitle": "Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["B-Cell Non-Hodgkin Lymphoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Leukemia", "Lymphoma", "Plasma Cell Myeloma", "T-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06875128",
          "briefTitle": "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer in the Liver"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03580928",
          "briefTitle": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Lymphocytic Leukemia (CLL)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06507800",
          "briefTitle": "Cancer as a complicATion in reCipients of Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease iNdiCation trEated in FRance and Canada?"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Autoimmune Diseases"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04387500",
          "briefTitle": "Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Renal Cell", "Fumarate Hydratase Deficiency", "Immunotherapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04033107",
          "briefTitle": "High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Cancer", "Pancreatic Cancer", "Gastric Cancer", "Colorectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00079092",
          "briefTitle": "Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2006-03-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04220892",
          "briefTitle": "Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-08",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2020-07-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "High Grade Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00804336",
          "briefTitle": "Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-10"
          },
          "completionDateStruct": {
            "date": "2015-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroendocrine Tumor", "Carcinoid Tumor", "Pancreatic Neuroendocrine Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01647971",
          "briefTitle": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Hodgkins Lymphoma", "B-cell Lymphoma", "Waldenstrom's Macroglobulinemia", "Marginal Zone Lymphoma", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Primary Central Nervous System Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06752044",
          "briefTitle": "Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced NSCLC"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04478695",
          "briefTitle": "Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01697072",
          "briefTitle": "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-10"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 609,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00726739",
          "briefTitle": "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-06"
          },
          "completionDateStruct": {
            "date": "2011-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Stage IV Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06357377",
          "briefTitle": "A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pediatric Tumor of CNS", "Pediatric Tumor of Brain", "Diffuse Midline Glioma, H3 K27M-Mutant", "Pediatric Tumor of Brain Stem", "Pineocytoma", "Choroid Plexus Carcinoma, Childhood", "Spinal Cord Tumor", "High Grade Glioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "5 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02076477",
          "briefTitle": "The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01"
          },
          "completionDateStruct": {
            "date": "2020-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Oligo-metastatic Stage IV Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 420,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00429572",
          "briefTitle": "Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1998-01"
          },
          "completionDateStruct": {
            "date": "2008-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06702995",
          "briefTitle": "Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-04-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Castrate-Resistant Prostate Cancer", "mCRPC (Metastatic Castration-resistant Prostate Cancer)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 307,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01663857",
          "briefTitle": "A Study LY2228820 for Recurrent Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07"
          },
          "completionDateStruct": {
            "date": "2018-05-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 118,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06445881",
          "briefTitle": "Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non Small Cell Lung Cancer", "Perioperative Complication"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00562419",
          "briefTitle": "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-10"
          },
          "completionDateStruct": {
            "date": "2011-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Brain and Central Nervous System Tumors", "Recurrent Glioblastoma Multiforme"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05458219",
          "briefTitle": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced Unresectable or Metastatic Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 470,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01250119",
          "briefTitle": "A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-03"
          },
          "completionDateStruct": {
            "date": "2014-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Squamous Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 688,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00823719",
          "briefTitle": "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2011-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03361319",
          "briefTitle": "Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["NSCLC, Recurrent", "Adenocarcinoma of Lung"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01797965",
          "briefTitle": "Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-02-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-09-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsing-Remitting Multiple Sclerosis", "Multiple Sclerosis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1501,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03884192",
          "briefTitle": "Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 162,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05078671",
          "briefTitle": "Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03859544",
          "briefTitle": "Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Central Nervous System Lymphoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01215344",
          "briefTitle": "First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-11"
          },
          "completionDateStruct": {
            "date": "2018-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06605664",
          "briefTitle": "Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma (HCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00691509",
          "briefTitle": "Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-01"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2300,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05261399",
          "briefTitle": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-17",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma", "Non-Small-Cell Lung"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 324,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06470672",
          "briefTitle": "Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03952572",
          "briefTitle": "Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peripheral T-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 244,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06485739",
          "briefTitle": "Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00191477",
          "briefTitle": "Instillation of Gemcitabine in Patients With Superficial Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-01"
          },
          "completionDateStruct": {
            "date": "2008-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Bladder Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 355,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00338377",
          "briefTitle": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1230,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03356912",
          "briefTitle": "CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancer", "Castration-resistant Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 220,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01678430",
          "briefTitle": "A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Lymphocytic Leukaemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 670,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00837200",
          "briefTitle": "Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-03"
          },
          "completionDateStruct": {
            "date": "2013-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-hodgkins Lymphoma", "Hodgkins Lymphoma", "Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05810792",
          "briefTitle": "Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Cancer", "Surgery", "Metastasis", "Immunosuppression"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01719536",
          "briefTitle": "Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12"
          },
          "completionDateStruct": {
            "date": "2017-02-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "NSCLC"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 296,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02652871",
          "briefTitle": "LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00191607",
          "briefTitle": "A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-07"
          },
          "completionDateStruct": {
            "date": "2005-11"
          }
        },
        "conditionsModule": {
          "conditions": ["Genital Neoplasms, Female", "Fallopian Tube Neoplasms", "Ovarian Neoplasms", "Pelvic Neoplasms", "Peritoneal Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 162
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02467907",
          "briefTitle": "Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      }
    ]
  }
}
